ATYR geopolitical news & exposure

ATYR geopolitical news and exposure. ATYR appears in 231 Geopolitics Alpha notes. The newest is 18 Sep 2026, 15:51 UTC. Stored price-reaction rows cover 0 of those notes.

• Xenon shares fall following depression trial pause

  18 Sep 2026, 15:51 UTC

• Ultragenyx prices Sanfilippo gene therapy at $4M; Bristol Myers shelves Orum drug

  18 Sep 2026, 14:24 UTC

• Neptune Medical wins FDA nod for endoscopy robot

  18 Sep 2026, 14:00 UTC

• Electra amasses $350M in biotech’s latest big IPO

  18 Sep 2026, 00:42 UTC

• Presidential Determination on Major Drug Transit or Major Illicit Drug Producing Countries for Fiscal Year 2027

  18 Sep 2026, 00:00 UTC

• Lisata deal propels Marea’s drug pipeline to Wall Street

  17 Sep 2026, 21:39 UTC

• FDA Approves First Gene Therapy for Pediatric Patients with Sanfilippo Syndrome Type A

  17 Sep 2026, 18:26 UTC

• North Immunology joins biotech reverse merger boom with Aethlon deal

  17 Sep 2026, 15:09 UTC

• Recor Medical ex-CEO Lara Barghout joins Medtronic

  16 Sep 2026, 19:52 UTC

• White House chief of staff Susie Wiles says she's cancer free

  16 Sep 2026, 19:31 UTC

• TTD Expands Pharma Reach: Can New Healthcare Integrations Drive Growth

  16 Sep 2026, 13:04 UTC

• FDA clears first generic radioligand drug; Sionna turns to layoffs

  15 Sep 2026, 21:13 UTC

• Is Cancer the Turnaround Moderna Has Been Looking for Post-COVID?

  15 Sep 2026, 16:24 UTC

• WCLC ‘26: A new ‘ADC era,’ China questions and AstraZeneca’s spotlight

  15 Sep 2026, 16:02 UTC

• FDA launches pilot program to speed up early US drug research

  15 Sep 2026, 14:00 UTC

• FDA Launches Expedited IND Pilot, Begins Accepting Applications

  15 Sep 2026, 13:53 UTC

• Summit, Akeso look to shed PD-1/VEGF drug doubts with latest study results

  14 Sep 2026, 20:41 UTC

• Beta Bionics’ insulin patch pump gets FDA nod

  14 Sep 2026, 19:22 UTC

• AstraZeneca’s newly approved pill fails frontline breast cancer study

  14 Sep 2026, 16:30 UTC

• Cellectis quits CAR-T and pivots to ‘in vivo’ gene editing

  14 Sep 2026, 15:46 UTC

• Cellectis quits CAR-Ts and pivots to ‘in vivo’ gene editing

  14 Sep 2026, 15:46 UTC

• GSK Presents Jideytro Data for Potential Use in First-Line NSCLC

  14 Sep 2026, 15:14 UTC

• Novo Nordisk is changing its name and its culture to try to compete in the GLP-1 diet-drug wars

  14 Sep 2026, 14:05 UTC

• Novo drops ‘Nordisk’ in corporate refresh to take on Lilly in the weight-loss wars

  14 Sep 2026, 13:20 UTC

• Scholar Rock SMA drug approved by FDA

  14 Sep 2026, 13:00 UTC

• Human factors isn’t a checkbox: What FDA’s eSTAR requirements mean for MedTech submissions

  14 Sep 2026, 09:00 UTC

• AstraZeneca COPD Drug Cuts Exacerbations as FDA Priority Review Nears

  13 Sep 2026, 10:01 UTC

• Tonix Pharmaceuticals Targets TONMYA Growth as Lyme Prevention Trial Nears

  12 Sep 2026, 02:01 UTC

• This week in charts: RA’s insatiable appetite, Novartis’ big slide and a reverse merger spree

  11 Sep 2026, 15:22 UTC

• FDA places partial hold on Biohaven’s epilepsy drug

  10 Sep 2026, 16:13 UTC

• Kura spins diabetes work into a Lilly-backed biotech startup

  09 Sep 2026, 15:54 UTC